eligibility_summary
Eligible: adults ≥40 with newly diagnosed Ph− precursor B‑cell ALL (WHO 2022), ECOG 0–2, life expectancy ≥3 months, adequate organ function, informed consent, and effective contraception during treatment and 12 months after. Exclude: CNS leukemia, significant cardiac/pulmonary/hepatic/renal disease, LVEF <45%, other recent malignancy, high bilirubin/ALT/AST/creatinine, HIV, investigator-unsuitable, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in adult Ph− precursor B-ALL testing: Blinatumomab (BiTE antibody, engages CD3 on T cells and CD19 on leukemic B cells to drive T‑cell cytotoxicity), Venetoclax (oral small‑molecule BCL‑2 inhibitor restoring intrinsic apoptosis), and Inotuzumab ozogamicin (anti‑CD22 antibody–drug conjugate delivering calicheamicin to CD22+ blasts). Additional agents: Dexamethasone (glucocorticoid inducing lymphoid apoptosis), High‑dose Methotrexate (antifolate inhibiting DHFR and nucleotide synthesis), Pegaspargase (asparagine depletion), Cytarabine (pyrimidine analog inhibiting DNA polymerase). Targets/pathways: CD19+ and CD22+ B‑cell blasts, T‑cell engagement via CD3, BCL‑2 anti‑apoptotic pathway, folate/nucleotide synthesis, asparagine metabolism, DNA replication.